Weeding out the truth: a systematic review and meta-analysis on the transition from cannabis use to opioid use and opioid use disorders, abuse or dependence.
Cannabis
gateway
opioid use disorders
opioids
substance use
transition
Journal
Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
18
01
2021
received:
11
10
2020
accepted:
12
05
2021
pubmed:
16
7
2021
medline:
2
2
2022
entrez:
15
7
2021
Statut:
ppublish
Résumé
The idea that cannabis is a 'gateway drug' to more harmful substances such as opioids is highly controversial, yet has substantially impacted policy, education and how we conceptualize substance use. Given a rise in access to cannabis products and opioid-related harm, the current study aimed to conduct the first systematic review and meta-analysis on the likelihood of transitioning from cannabis use to subsequent first-time opioid use, opioid use disorders (OUD), dependence or abuse. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, pubMed/MEDLINE, Scopus, EMBASE, PsychINFO, Cochrane Central Register of Controlled Trials and Informit Health Collection were searched for full-text articles assessing the likelihood of transitioning from cannabis to subsequent opioid use, and from opioid use to OUD, abuse or dependence given prior cannabis use. Analysis of subpopulations within studies were discussed narratively, and E-values were calculated to assess the potential influence of unmeasured confounding. Six studies provided relevant data from the United States, Australia and New Zealand between 1977 and 2017, a total sample of 102 461 participants. Random-effects analysis of the adjusted pooled effect size indicates that the likelihood of transitioning from cannabis to opioid use, relative to non-cannabis users, is odds ratio (OR) = 2.76, 95% confidence interval (CI) = 2.26-3.36, whereas the likelihood of transitioning from opioid use to OUD, abuse or dependence given prior cannabis use is OR = 2.52, 95% CI = 1.65-3.84. While the evidence was determined to be of low quality with moderate risk of bias, E-values suggest that these findings are robust against unmeasured confounding. A systematic review and meta-analysis found that while people who use cannabis are disproportionately more likely to initiate opioid use and engage in problematic patterns of use than people who do not use cannabis, the low quality of the evidence must be considered when interpreting these findings.
Sections du résumé
BACKGROUND AND AIMS
The idea that cannabis is a 'gateway drug' to more harmful substances such as opioids is highly controversial, yet has substantially impacted policy, education and how we conceptualize substance use. Given a rise in access to cannabis products and opioid-related harm, the current study aimed to conduct the first systematic review and meta-analysis on the likelihood of transitioning from cannabis use to subsequent first-time opioid use, opioid use disorders (OUD), dependence or abuse.
METHODS
Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, pubMed/MEDLINE, Scopus, EMBASE, PsychINFO, Cochrane Central Register of Controlled Trials and Informit Health Collection were searched for full-text articles assessing the likelihood of transitioning from cannabis to subsequent opioid use, and from opioid use to OUD, abuse or dependence given prior cannabis use. Analysis of subpopulations within studies were discussed narratively, and E-values were calculated to assess the potential influence of unmeasured confounding.
FINDINGS
Six studies provided relevant data from the United States, Australia and New Zealand between 1977 and 2017, a total sample of 102 461 participants. Random-effects analysis of the adjusted pooled effect size indicates that the likelihood of transitioning from cannabis to opioid use, relative to non-cannabis users, is odds ratio (OR) = 2.76, 95% confidence interval (CI) = 2.26-3.36, whereas the likelihood of transitioning from opioid use to OUD, abuse or dependence given prior cannabis use is OR = 2.52, 95% CI = 1.65-3.84. While the evidence was determined to be of low quality with moderate risk of bias, E-values suggest that these findings are robust against unmeasured confounding.
CONCLUSION
A systematic review and meta-analysis found that while people who use cannabis are disproportionately more likely to initiate opioid use and engage in problematic patterns of use than people who do not use cannabis, the low quality of the evidence must be considered when interpreting these findings.
Substances chimiques
Analgesics, Opioid
0
Hallucinogens
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
284-298Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2021 Society for the Study of Addiction.
Références
Kandel D. Stages in adolescent involvement in drug use. Science 1975; 190: 912-914.
Yamaguchi K., Kandel D. B. Patterns of drug use from adolescence to young adulthood: II. Sequences of progression. Am J Public Health 1984; 74: 668-672.
Fergusson D. M., Horwood L. J. Does cannabis use encourage other forms of illicit drug use? Addiction 2000; 95: 505-520.
Kendler K. S., Karkowski L. M., Corey L. A., Prescott C. A., Neale M. C. Genetic and environmental risk factors in the aetiology of illicit drug initiation and subsequent misuse in women. Br J Psychiatry 1999; 175: 351-356.
Morral A. R., McCaffrey D. F., Paddock S. M. Reassessing the marijuana gateway effect. Addiction 2002; 97: 1493-1504.
Degenhardt L., Charlson F., Ferrari A., Santomauro D., Erskine H., Mantilla-Herrara A., et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease study 2016. Lancet Psychiatry 2018; 5: 987-1012.
Australian Institute of Health and Welfare (AIHW). National Drug Strategy Household Survey 2016: Detailed Findings. Drug Statistics series no. 31. Cat. no. PHE 214. Canberra: AIHW. 2017.
European Monitoring Centre for Drugs and Drug Addiction European Drug Report, Vol. 2020. Luxembourg: Trends and Developments, Publications Office of the European Union; 2020.
Alcover K. C., Thompson C. L. Patterns of mean age at drug use initiation among adolescents and emerging adults, 2004-2017. JAMA Pediatr 2020; 174: 725-727.
Fergusson D. M., Boden J. M., Horwood L. J. Psychosocial sequelae of cannabis use and implications for policy: findings from the Christchurch health and development study. Soc Psychiatry Psychiatr Epidemiol 2015; 50: 1317-1326.
Olfson M., Wall M. M., Liu S. M., Blanco C. Cannabis use and risk of prescription opioid use disorder in the United States. Am J Psychiatry 2018; 175: 47-53.
Agrawal A., Neale M. C., Prescott C. A., Kendler K. S. A twin study of early cannabis use and subsequent use and abuse/dependence of other illicit drugs. Psychol Med 2004; 34: 1227-1237.
Lynskey M. T., Heath A. C., Bucholz K. K., Slutske W. S., Madden P. A., Nelson E. C., et al. Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA 2003; 289: 427-433.
Degenhardt L., Chiu W. T., Conway K., Dierker L., Glantz M., Kalaydjian A., et al. Does the ‘gateway’ matter? Associations between the order of drug use initiation and the development of drug dependence in the National Comorbidity Study Replication. Psychol Med 2009; 39: 157-167.
Degenhardt L., Dierker L., Chiu W. T., Medina-Mora M. E., Neumark Y., Sampson N., et al. Evaluating the drug use ‘gateway’ theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO world mental health surveys. Drug Alcohol Depend 2010; 108: 84-97.
World Drug Report. United Nations publication, Sales No. E.20.XI.6. 2020. Available at: https://wdr.unodc.org/wdr2020/field/WDR20_Booklet_2.pdf (accessed 10 July 2020).
Marel C., Sunderland M., Mills K. L., Slade T., Teesson M., Chapman C. Conditional probabilities of substance use disorders and associated risk factors: progression from first use to use disorder on alcohol, cannabis, stimulants, sedatives and opioids. Drug Alcohol Depend 2019; 194: 136-142.
Reinhart M., Scarpati L. M., Kirson N. Y., Patton C., Shak N., Erensen J. G. The economic burden of abuse of prescription opioids: a systematic literature review from 2012 to 2017. Appl Health Econ Health Policy 2018; 16: 609-632.
DuPont R. L. Getting Tough on Gateway Drugs. Washington, DC: American Psychiatric Press; 1984.
Bell K., Keane H. All gates lead to smoking: the ‘gateway theory’, e-cigarettes and the remaking of nicotine. Soc Sci Med 2014; 119: 45-52.
Hasan A., von Keller R., Friemel C. M., Hall W., Schneider M., Koethe D., et al. Cannabis use and psychosis: a review of reviews. Eur Arch Psychiatry Clin Neurosci 2020; 270: 403-412.
R Core Team. R A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2017.
Higgins J. P., Green S. Cochrane Handbook for Systematic Reviews of Interventions. Hoboken, NJ: John Wiley & Sons; 2011.
Ryan R., Hill S. Cochrane Consumers and Communication Group: How to GRADE the Quality of the Evidence, version 3.0. December 2016. Available at: http://cccrg.cochrane.org/author-resources (accessed 27 August 2020).
Sterne J. A., Hernán M. A., Reeves B. C., Savović J., Berkman N. D., Viswanathan M., et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919.
VanderWeele T. J., Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med 2017; 167: 268-274.
Fiellin L. E., Tetrault J. M., Becker W. C., Fiellin D. A., Hoff R. A. Previous use of alcohol, cigarettes, and marijuana and subsequent abuse of prescription opioids in young adults. J Adolesc Health 2013; 52: 158-163.
Grant J. D., Lynskey M. T., Scherrer J. F., Agrawal A., Heath A. C., Bucholz K. K. A cotwin-control analysis of drug use and abuse/dependence risk associated with early-onset cannabis use. Addict Behav 2010; 35: 35-41.
De Vita M. J., Moskal D., Maisto S. A., Ansell E. B. Association of cannabinoid administration with experimental pain in healthy adults: a systematic review and meta-analysis. JAMA Psychiatry 2018; 75: 1118-1127.
Campbell G., Hall W. D., Peacock A., Lintzeris N., Bruno R., Larance B., et al. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health 2018; 3: e341-e350.
Scavone J. L., Sterling R. C., Weinstein S. P., Van Bockstaele E. J. Impact of cannabis use during stabilization on methadone maintenance treatment. Am J Addict 2013; 22: 344-351.
Wilson-Poe A. R., Pocius E., Herschbach M., Morgan M. M. The periaqueductal gray contributes to bidirectional enhancement of antinociception between morphine and cannabinoids. Pharmacol Biochem Behav 2013; 103: 444-449.
Keyes K. M., Rutherford C., Miech R. Historical trends in the grade of onset and sequence of cigarette, alcohol, and marijuana use among adolescents from 1976-2016: implications for ‘gateway’ patterns in adolescence. Drug Alcohol Depend 2019; 194: 51-58.
Australian Institute of Health and Welfare (AIHW). National Drug Strategy Household Survey 2019. Drug Statistics series no. 32. PHE 270. Canberra, Australia: AIHW; 2020.
Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication no. PEP20-07-01-001, NSDUH Series H-55). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services administration; 2020. Available at: https://www.samhsa.gov/data/ (accessed 30 September 2020).
Davies N. M., Holmes M. V., Davey S. G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 2018; 362: k601.